Opinion statement
Primary amyloidosis is a plasma cell dyscrasia in which insoluble immunoglobulin light chain fragments are produced and polymerize into fibrils that deposit extracellularly, causing visceral organ dysfunction and death. The disorder is rare. Its recognition requires understanding the association between nephrotic syndrome, cardiomyopathy, peripheral neuropathy, and hepatomegaly with amyloidosis. The most important screening test for amyloidosis is immunofixation of the serum and urine to detect a monoclonal immunoglobulin light chain. All patients need the diagnosis confirmed histologically. The least invasive source of tissue for amyloid detection is the subcutaneous fat. The most important prognostic factor is whether there is cardiac involvement, which is best assessed by echocardiography with Doppler studies. Therapies used include oral melphalan/prednisone and high-dose corticosteroids. High-dose chemotherapy followed by stem cell reconstitution seems to provide the highest reported response rates. Transplant is associated with unique morbidities not seen in the transplantation of patients with other hematologic malignancies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Rukavina JG, Block WD, Jackson CE, et al.: Primary systemic amyloidosis: a review and an experimental, genetic, and clinical study of 29 cases with particular emphasis on the familial form. Medicine (Baltimore) 1993, 72:45–63.
Gertz MA: Secondary amyloidosis (AA). J Intern Med 1992, 232:517–518.
Solomon A, Weiss DT, Murphy C: Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis). Am J Hematol 1994, 45:171–176.
Solomon A, Weiss DT, Pepys MB: Induction in mice of human light-chain-associated amyloidosis. Am J Pathol 1992, 140:629–637.
Rajkumar SV, Gertz MA, Kyle RA: Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998, 82:1501–1505.
Kyle RA, Linos A, Beard CM, et al.: Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992, 79:1817–1822.
Waterhouse D, Carman WJ, Schottenfeld D, et al.: Cancer incidence in the rural community of Tecumseh, Michigan: a pattern of increased lymphopoietic neoplasms. Cancer 1996, 77:763–770.
Gertz MA, Kyle RA: Primary systemic amyloidosis- a diagnostic primer. Mayo Clin Proc 1989, 64:1505–1519.
Rodon P, Friocourt P, Blanchet S, Levallois D: Temporal artery involvement revealing AL amyloidosis and IgD monoclonal gammopathy. J Rheumatol 1996, 23:189–190.
Rao JK, Allen NB: Primary systemic amyloidosis masquerading as giant cell arteritis: case report and review of the literature. Arthritis Rheum 1993, 36:422–425.
Gertz MA, Kyle RA, Griffing WL, Hunder GG: Jaw claudication in primary systemic amyloidosis. Medicine (Baltimore) 1986, 65:173–179.
Gertz MA, Kyle RA: Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry 1996, 60:655–660.
Schlesinger I: Multiple myeloma and AL amyloidosis mimicking Sjögren’s syndrome. South Med J 1993, 86:568–569.
Richey TK, Bennion SD: Etiologies of the sicca syndrome: primary systemic amyloidosis and others. Int J Dermatol 1996, 35:553–557.
Schena FP, Pannarale G, Carbonara MC: Clinical and therapeutic aspects of renal amyloidosis. Nephrol Dial Transplant 1996, 11:63–68.
Peters RA, Koukoulis G, Gimson A, et al.: Primary amyloidosis and severe intrahepatic cholestatic jaundice. Gut 1994, 35:1322–1325.
Rajkumar SV, Gertz MA, Kyle RA: Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998, 104:232–237.
Kyle RA, Gertz MA: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995, 32:45–59.
Pascali E: Diagnosis and treatment of primary amyloidosis. Crit Rev Oncol Hematol 1995, 19:149–181.
Feiner HD: Pathology of dysproteinemia: light chain amyloidosis, non-amyloid immunoglobulin deposition disease, cryoglobulinemia syndromes, and macroglobulinemia of Waldenström. Hum Pathol 1988, 19:1255–1272.
Gertz MA, Greipp PR, Kyle RA: Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow. J Lab Clin Med 1991, 118:33–39.
Wu SS, Brady K, Anderson JJ, et al.: The predictive value of bone marrow morphologic characteristics and immunostaining in primary (AL) amyloidosis. Am J Clin Pathol 1991, 96:95–99.
Gillmore JD, Hawkins PN, Pepys MB: Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol 1997, 99:245–256.
Westermark P: Diagnosing amyloidosis [editorial]. Scand J Rheumatol 1995, 24:327–329.
Hachulla E, Janin A, Flipo RM, et al.: Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis: a prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum 1993, 36:691–697.
Huang CY, Wang WJ, Wong CK: Skin biopsy gives the potential benefit in the diagnosis of systemic amyloidosis associated with cardiovascular involvement [letter]. Arch Dermatol 1998, 134:643–645.
Cueto-Garcia L, Tajik AJ, Kyle RA, et al.: Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc 1984, 59:589–597.
Gertz MA, Kyle RA: Amyloidosis: prognosis and treatment. Semin Arthritis Rheum 1994, 24:124–138.
Kyle RA, Greipp PR, O’Fallon WM: Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986, 68:220–224.
Chamarthi B, Dubrey SW, Cha K, et al.: Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol 1997, 80:1242–1245.
Tei C, Dujardin KS, Hodge DO, et al.: Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol 1996, 28:658–664.
Hongo M, Kono J, Yamada H, et al.: Doppler echocardiographic assessments of left ventricular diastolic filling in patients with amyloid heart disease. J Cardiol 1991, 21:391–401.
Klein AL, Hatle LK, Taliercio CP, et al.: Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis: a Doppler echocardiography study. Circulation 1991, 83:808–816.
Kyle RA, Gertz MA, Greipp PR, et al.: A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997, 336:1202–1207.
Skinner M, Anderson J, Simms R, et al.: Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996, 100:290–298.
Gertz MA, Kyle RA, Greipp PR: Response rates and survival in primary systemic amyloidosis. Blood 1991, 77:257–262.
Gertz MA, Kyle RA: Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 1990, 150:629–633.
Gertz MA, Kyle RA: Phase II trial of alpha-tocopherol (vitamin E) in the treatment of primary systemic amyloidosis. Am J Hematol 1990, 34:55–58.
Gertz MA, Kyle RA: Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. Am J Hematol 1993, 44:125–128.
Dhodapkar MV, Jagannath S, Vesole D, et al.: Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 1997, 27:351–356.
Sezer O, Schmid P, Shweigert M, et al.: Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 1999, 23:967–969.
Gianni L, Bellotti V, Gianni AM, Merlini G: New drug therapy of amyloidoses: resorption of AL-type deposits with 4’-iodo-4’-deoxydoxorubicin. Blood 1995, 86:855–861.
Sebastiao MP, Merlini G, Saraiva MJ, Damas AM: The molecular interaction of 4’-iodo-4’-deoxydoxorubicin with Leu-55Pro transthyretin ‘amyloid-like’ oligomer leading to disaggregation. Biochem J 2000, 351:273–279.
Palha JA, Ballinari D, Amboldi N, et al.: 4’-iodo-4’-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol 2000, 156:1919–1925.
Gertz MA, Lacy MQ, Lust JA, et al.: Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999, 17:262–267.
Dubrey S, Simms RW, Skinner M, Falk RH: Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival. Am J Cardiol 1995, 76:739–741.
Pelosi F Jr, Capehart J, Roberts WC: Effectiveness of cardiac transplantation for primary (AL) cardiac amyloidosis. Am J Cardiol 1997, 79:532–535.
Gertz MA, Lacy MQ, Dispenzieri A: Myeloablative chemotherapy with stem cell rescue for the treatment of primary amyloidosis: a status report. Bone Marrow Transplant 2000, 25:465–470.
Dispenzieri A, Lacy MQ, Kyle RA, et al.: Eligibility for hematopoietic stem-cell transplantation for primary systemic favorable prognostic factor for survival. J Clin Oncol 2001, 19:3350–3356.
Gertz MA, Lacy MQ, Dispenzieri A: Amyloidosis (AL). In Myeloma. Edited by Mehta J, Singhal S. London: Martin Dunitz; 2002:445-464.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gertz, M.A., Rajkumar, S.V. Primary systemic amyloidosis. Curr. Treat. Options in Oncol. 3, 261–271 (2002). https://doi.org/10.1007/s11864-002-0016-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11864-002-0016-1